Compare ASTL & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTL | MRVI |
|---|---|---|
| Founded | 1902 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 467.0M | 472.8M |
| IPO Year | N/A | 2020 |
| Metric | ASTL | MRVI |
|---|---|---|
| Price | $4.14 | $2.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 1.4M | ★ 1.8M |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.21% | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $185,743,000.00 |
| Revenue This Year | N/A | $12.44 |
| Revenue Next Year | $25.68 | $7.90 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.02 | $1.67 |
| 52 Week High | $7.25 | $4.11 |
| Indicator | ASTL | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 50.74 | 40.87 |
| Support Level | $3.99 | $2.88 |
| Resistance Level | $4.29 | $3.20 |
| Average True Range (ATR) | 0.24 | 0.15 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 82.45 | 30.61 |
Algoma Steel Group Inc is a fully integrated steel producer of hot and cold rolled steel products, including coiled sheet and plate, strategically located. The firm operates in a single segment of basic steel production including sheets, plates, slabs, and freights. The company's revenue is generated from contracts to produce, ship, and deliver steel products Geographically it serves Canada, the United States, and the rest of the world, whilst driving key revenue from domestic sales. The company generates the majority of its revenue from the sale of Steel sheets and strips.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.